Transdermal estradiol in castrate and chemotherapy resistant prostate cancer

BACKGROUND: Given prior studies demonstrating the marked clinical activity of oral estrogens in prostate cancer, more recent data demonstrating the safety of transdermal estradiol, and the renewed interest in targeting testosterone metabolism and androgen receptor pathways, we report the results of...

Descripción completa

Detalles Bibliográficos
Autores principales: Stein, Mark, Goodin, Susan, Doyle-Lindrud, Susan, Silberberg, Jeffrey, Kane, Michael, Metzger, Dorinda, Eddy, Simantini, Shih, Weichung, DiPaola, Robert S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2012
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3560819/
https://www.ncbi.nlm.nih.gov/pubmed/22460098
http://dx.doi.org/10.12659/MSM.882626

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3560819/
https://www.ncbi.nlm.nih.gov/pubmed/22460098
http://dx.doi.org/10.12659/MSM.882626

Ejemplares similares